US Stock Insider Trading | Exagen Disclosed Two Insider Transactions on February 25

K-LinePoet · 2026-03-15T20:16:12+00:00

Exagen disclosed insider trading activity on February 25, 2026, in which Director ABALLI JOHN sold 11,400 shares on February 24. Executive Black Jeffrey G. also conducted a transaction. Exagen is committed to improving care for chronic autoimmune disease patients through precise diagnostic identification and therapeutic intervention.

K-LinePoet

2026-03-15 20:16:12

Abstract generation in progress

On February 25, 2026, Exagen (XGN) disclosed two insider trading transactions. Director ABALLI JOHN sold 11,400 shares on February 24, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 25, 2026	Executive	Black Jeffrey G.	February 24, 2026	Sell	1,584	3.61	5,718.24
February 25, 2026	Director	ABALLI JOHN	February 24, 2026	Sell	11,400	3.61	41,300
October 20, 2025	Director	ABALLI JOHN	October 16, 2025	Sell	31,800	11.82	375,600
September 4, 2025	Executive	Black Jeffrey G.	September 2, 2025	Sell	20,500	9.79	200,400
March 27, 2025	Shareholder with >10%	NMSIC Co-Investment Fund, L.P.	March 25, 2025	Sell	350,000	3.30	1,155,000
March 4, 2025	Director	ABALLI JOHN	February 28, 2025	Buy	8,621	2.47	21,300
November 27, 2024	Shareholder with >10%	NMSIC Co-Investment Fund, L.P.	November 20, 2024	Sell	200,000	3.30	660,000
November 19, 2024	Executive	Black Jeffrey G.	November 15, 2024	Buy	22,300	2.98	66,400
May 16, 2024	Director	ABALLI JOHN	May 16, 2024	Buy	40,400	1.92	77,600
March 6, 2024	Executive	Adawi Kamal	March 4, 2024	Sell	3,487	1.91	6,660

[Company Profile]

Exagen Inc. was founded in 2002. Exagen is dedicated to transforming patient care for those with frailty and chronic autoimmune diseases through timely diagnostics and optimized treatment interventions. The company’s goal is to enable rheumatologists to improve patient care by identifying, prognosing, and monitoring complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.